Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01192295
Registration number
NCT01192295
Ethics application status
Date submitted
30/08/2010
Date registered
1/09/2010
Date last updated
23/03/2020
Titles & IDs
Public title
Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
Query!
Scientific title
An Open-label, Multicenter Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children From Ages 6 to 16 Years Old, Inclusive, With Moderate to Severe Malignant and/or Nonmalignant Pain Requiring Opioid Analgesics
Query!
Secondary ID [1]
0
0
2010-020471-23
Query!
Secondary ID [2]
0
0
OTR3001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pain
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Oxycodone HCl controlled-release tablets
Experimental: Oxycodone HCl controlled-release - Oxycodone hydrochloride (HCl) controlled-release (CR)
Treatment: Drugs: Oxycodone HCl controlled-release tablets
Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
The Number of Participants With Adverse Events as a Measure of Safety.
Query!
Assessment method [1]
0
0
Safety assessments consisted of reports of AEs, physical examinations, clinical laboratory test results, vital signs measurements, pulse oximetry (SpO2), and somnolence assessments. Safety variables were summarized descriptively within age group for the safety population.
Query!
Timepoint [1]
0
0
Up to 4 weeks (during the study) and 7-10 days poststudy (safety follow-up assessment).
Query!
Secondary outcome [1]
0
0
Pain Right Now Assessment by Patients Aged 6 to < 12 Years
Query!
Assessment method [1]
0
0
Pain right now was assessed by patients aged 6 to <12 years using the Faces of Pain Scale-Revised (FPS-R). The FPS-R is a horizontal row of 6 faces representing pain intensity, with "no hurt" at the far left and "hurts worst" at the far right; the 6 intensities are scored as 0, 2, 4, 6, 8, or 10 (the patient was not shown the numbers associated with the faces). A score of 0 means no pain, and a 10 means very much pain. Pain right now was assessed by the patient at screening; after the first dose; and, thereafter, twice daily during the AM and PM, approximately at the time of each (morning and evening) dose of oxycodone HCl CR tablets during the study treatment.
Query!
Timepoint [1]
0
0
Baseline to week 4
Query!
Secondary outcome [2]
0
0
Pain Right Now Assessment by Patients Aged = 12 to = 16 Years
Query!
Assessment method [2]
0
0
Pain right now was assessed by patients aged = 12 to = 16 years using the 100-mm visual analogue scale (VAS). The 100-mm VAS is a 100-mm line with 1 end marked "no pain" and the opposite end marked as "pain as bad as it could be." The patient was asked to make a mark on that line indicating his or her level of pain. The pain right now 100-mm VAS score was defined as the distance (in mm) from the "no pain" end to the patient's mark. The scale is measured on a 100 mm line: a 0 means no pain and bigger numbers indicate more pain. Pain right now was assessed by the patient at screening; after the first dose; and, thereafter, twice daily during the AM and PM, approximately at the time of each (morning and evening) dose of oxycodone HCl CR tablets during the study treatment.
Query!
Timepoint [2]
0
0
Baseline to week 4
Query!
Secondary outcome [3]
0
0
Use of Supplemental Pain Medication
Query!
Assessment method [3]
0
0
Supplemental opioid and nonopioid pain medications were permitted during the study as deemed appropriate by the investigator. The dose of supplemental analgesic medication allowed was at the discretion of the investigator and within appropriate dose ranges for age and weight.
Query!
Timepoint [3]
0
0
Baseline to week 4
Query!
Secondary outcome [4]
0
0
Parent/ Caregiver-Assessed Global Impression of Change (PGIC)
Query!
Assessment method [4]
0
0
The PGIC rating score variable was collected on a 7-point scale ranging from 1 to 7 (where 1 = very much improved; and 7 = very much worse). The PGIC is designed to assess overall satisfaction with the treatment. The number and percent of parent/caregivers reporting each category of PGIC response at the final visit was summarized for the safety population within age group.
Query!
Timepoint [4]
0
0
Baseline to week 4 or early discontinuation
Query!
Secondary outcome [5]
0
0
Parent/ Caregiver Assessed Functional Disability Inventory (FDI) for Patients Aged 6 to < 12 Years
Query!
Assessment method [5]
0
0
The FDI is a validated tool used to evaluate the degree to which children have reduced physical and psychosocial functioning because of their pain difficulties in the previous 2 weeks. The FDI comprises 15 items. Responses to each item were scored using a 5-point Likert scale. The individual scores are: (0) no trouble, (1) a little trouble, (2) some trouble, (3) a lot of trouble, and (4) impossible. A total score (ranging from 0 to 60) for the 15 items was calculated, with lower scores indicating less functional disability. The FDI was performed by the parent/ caregiver.
Query!
Timepoint [5]
0
0
Baseline to week 4
Query!
Secondary outcome [6]
0
0
Parent/ Caregiver Assessed Functional Disability Inventory (FDI) for Patients Aged = 12 to = 16 Years
Query!
Assessment method [6]
0
0
The FDI is a validated tool used to evaluate the degree to which children have reduced physical and psychosocial functioning because of their pain difficulties in the previous 2 weeks. The FDI comprises 15 items. Responses to each item were scored using a 5-point Likert scale. The individual scores are: (0) no trouble, (1) a little trouble, (2) some trouble, (3) a lot of trouble, and (4) impossible. A total score (ranging from 0 to 60) for the 15 items was calculated, with lower scores indicating less functional disability. The FDI was performed by the parent/ caregiver.
Query!
Timepoint [6]
0
0
Baseline to week 4
Query!
Secondary outcome [7]
0
0
Pharmacokinetics (PK) Data of Oxycodone Hydrochloride Controlled-release Tablets
Query!
Assessment method [7]
0
0
A population PK analysis using sparse plasma concentration data in pediatric patients was conducted. Empirical Bayes estimates were used to calculate individual PK parameters. PK parameters were calculated and reported for each individual patient's first and last dose. Cmax was taken as the maximum simulated oxycodone concentration over the dosing interval and Cmin was the simulated oxycodone concentration when time was equal to 12 hours. Steady-state Cmin and Cmax were derived from the accumulation ratio.
The following PK parameters are presented: Cmin / Cmax (minimum / maximum concentration); Cmin,ss / Cmax,ss (Cmin / Cmax at steady state); CAVGss (average concentration at steady state).
Query!
Timepoint [7]
0
0
Day 1 - first dose [2-4 hrs post dose and 4-6 hrs post dose], week 4 - last dose [at pre-dose and at 2-4 hrs post dose]
Query!
Secondary outcome [8]
0
0
Pharmacokinetics (PK) Data of Oxycodone Hydrochloride Controlled-release Tablets - AUCtau and AUCss
Query!
Assessment method [8]
0
0
A population PK analysis using sparse plasma concentration data in pediatric patients was conducted. Empirical Bayes estimates were used to calculate individual PK parameters. PK parameters were calculated and reported for each individual patient's first and last dose. First-dose area under the concentration-time curve (AUC) was derived from the accumulation ratio. For all calculations, the dosing interval was assumed to be 12 hours.
The following PK parameters are presented: AUCtau (area under the concentration-time curve from time zero to time equal to dosing interval); AUCss (AUC at steady state).
Query!
Timepoint [8]
0
0
Day 1 - first dose [2-4 hrs post dose and 4-6 hrs post dose], week 4 - last dose [at pre-dose and at 2-4 hrs post dose]
Query!
Secondary outcome [9]
0
0
Pharmacokinetics (PK) Data of Oxycodone Hydrochloride Controlled-release Tablets - Time to Maximum Concentration (Tmax)
Query!
Assessment method [9]
0
0
A population PK analysis using sparse plasma concentration data in pediatric patients was conducted. Empirical Bayes estimates were used to calculate individual PK parameters. PK parameters were calculated and reported for each individual patient's first and last dose.
Query!
Timepoint [9]
0
0
Day 1 - first dose [2-4 hrs post dose and 4-6 hrs post dose], week 4 - last dose [at pre-dose and at 2-4 hrs post dose]
Query!
Secondary outcome [10]
0
0
Pharmacokinetics (PK) Data of Oxycodone Hydrochloride Controlled-release Tablets - Accumulation Ratio
Query!
Assessment method [10]
0
0
A population PK analysis using sparse plasma concentration data in pediatric patients was conducted. Empirical Bayes estimates were used to calculate individual PK parameters. PK parameters were calculated and reported for each individual patient's first and last dose. The accumulation ratio is used to derive steady-state Cmin and Cmax and first-dose area under the concentration-time curve (AUCtau).
Query!
Timepoint [10]
0
0
Day 1 - first dose [2-4 hrs post dose and 4-6 hrs post dose], week 4 - last dose [at pre-dose and at 2-4 hrs post dose]
Query!
Eligibility
Key inclusion criteria
Inclusion Criteria include:
- Male and female patients aged 6 to 16 years, inclusive, who are expected to require
ongoing around-the-clock opioid treatment equivalent to at least 20-mg daily dose of
oxycodone for at least 2 weeks for management of moderate to severe (based on the
investigator's judgment) malignant or nonmalignant pain.
- Patients must be opioid tolerant, ie, have been treated with opioids for at least the
5 consecutive days prior to dosing and with at least 20 mg daily of oxycodone or the
equivalent during at least the last 48 hours prior to the start of study drug dosing
and have tolerated the therapy, as demonstrated at the start of study drug dosing.
- Patients who are currently using transdermal fentanyl should have been on the patch
for at least 3 days before removing the patch and oxycodone hydrochloride (HCl)
controlled-release (CR) treatment can only be initiated at least 18 hours following
the removal of the transdermal fentanyl patch.
- Patients must not require more than a 240-mg total daily dose of oxycodone HCl CR
tablets.
- Patients must be willing and able to swallow the oxycodone HCl CR tablets whole.
- Patients must not be currently on an investigational medication/therapy at the start
of screening or during the study.
Query!
Minimum age
6
Years
Query!
Query!
Maximum age
16
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria include:
- Female patients who are pregnant or lactating.
- Patients who are allergic to oxycodone or have a history of allergies to other opioids
(this criterion does not include patients who have experienced common opioid side
effects [eg, nausea, constipation]).
- Patients who have received epidural opioids < 2 hours prior to the first dose of study
drug or who have received epidural morphine < 12 hours prior to the first dose of
study drug.
- Patients who are contraindicated for the use of opioids.
- Patients who are contraindicated for blood sampling.
- Patients who are currently being maintained on methadone for pain.
- Patients who have any planned surgery during the course of the study, with the
exception of the placement of central or peripheral venous access devices.
- Patients who have had surgery within 5 days prior to Day 1 (day of first dose of study
drug).
- Patients who, in the investigator's opinion, have an underlying gastrointestinal
condition or other disorder that may predispose them to obstruction.
Other protocol-specific inclusion/exclusion criteria may apply.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/11/2010
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/07/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
155
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Delaware
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kentucky
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Ohio
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Oklahoma
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Oregon
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Pennsylvania
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Tennessee
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Texas
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Utah
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Virginia
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Wisconsin
Query!
Country [23]
0
0
Greece
Query!
State/province [23]
0
0
Athens
Query!
Country [24]
0
0
Hungary
Query!
State/province [24]
0
0
Budapest
Query!
Country [25]
0
0
Israel
Query!
State/province [25]
0
0
Beersheba
Query!
Country [26]
0
0
Israel
Query!
State/province [26]
0
0
Haifa
Query!
Country [27]
0
0
Israel
Query!
State/province [27]
0
0
Jerusalem
Query!
Country [28]
0
0
Israel
Query!
State/province [28]
0
0
Peta? Tiqwa
Query!
Country [29]
0
0
Israel
Query!
State/province [29]
0
0
Ramat Gan
Query!
Country [30]
0
0
New Zealand
Query!
State/province [30]
0
0
Auckland
Query!
Country [31]
0
0
Romania
Query!
State/province [31]
0
0
Targu Mures
Query!
Country [32]
0
0
Spain
Query!
State/province [32]
0
0
Barcelona
Query!
Country [33]
0
0
United Kingdom
Query!
State/province [33]
0
0
Sheffield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Purdue Pharma LP
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to characterize the safety of oxycodone hydrochloride (HCl)
controlled-release (CR) tablets in opioid tolerant pediatric patients aged 6 to 16 years,
inclusive, with moderate to severe malignant and/or nonmalignant pain requiring opioid
therapy.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01192295
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01192295
Download to PDF